Status:

COMPLETED

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Lead Sponsor:

BioAtla, Inc.

Conditions:

Non-Small-Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Detailed Description

This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targete...

Eligibility Criteria

Inclusion

  • Patients must have measurable disease.
  • Age ≥ 18 years
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.

Exclusion

  • Patients must not have clinically significant cardiac disease.
  • Patients must not have known non-controlled CNS metastasis.
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3011
  • Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • Patients must not be women who are pregnant or breast feeding.

Key Trial Info

Start Date :

March 17 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 9 2025

Estimated Enrollment :

85 Patients enrolled

Trial Details

Trial ID

NCT04681131

Start Date

March 17 2021

End Date

July 9 2025

Last Update

September 25 2025

Active Locations (60)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (60 locations)

1

City of Hope - Duarte

Duarte, California, United States, 91010

2

University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center

Irvine, California, United States, 92868

3

California Research Institute

Los Angeles, California, United States, 90027

4

USC Norris

Los Angeles, California, United States, 90033